Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NZN8
UPID:
CNOT2_HUMAN
Alternative names:
CCR4-associated factor 2
Alternative UPACC:
Q9NZN8; Q9H3E0; Q9NSX5; Q9NWR6; Q9P028
Background:
CCR4-NOT transcription complex subunit 2, also known as CCR4-associated factor 2, plays a pivotal role in mRNA deadenylation, influencing bulk mRNA degradation, miRNA-mediated repression, and translational repression. It ensures the CCR4-NOT complex's structural integrity and is crucial for maintaining embryonic stem cell identity.
Therapeutic significance:
Linked to Intellectual developmental disorder with nasal speech, dysmorphic facies, and variable skeletal anomalies, understanding CCR4-NOT transcription complex subunit 2's role could unveil novel therapeutic strategies.